Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 178

Sort by

Sort Order Select

Journal Articles

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Blood blood.2024025868.

https://doi.org/10.1182/blood.2024025868

Published: 2024

Includes: Supplemental data

Journal Articles

Maintain maintenance in multiple myeloma?

Sonja Zweegman, Niels W. J. C. van de Donk

Blood (2023) 142 (18): 1501–1502.

https://doi.org/10.1182/blood.2023021781

Published: 2023

Journal Articles

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Blood (2023) 142 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2023-178882

Published: 2023

Journal Articles

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

Yan Beauverd, Jean-Christophe Ianotto, Kyaw Htin Thaw, Marta Sobas, Parvis Sadjadian, Natalia Curto-Garcia, Lee-Yung Shih, Timothy Devos, Dorota Krochmalczyk, Serena Galli, Maria Bieniaszewska, Ilona Seferynska, Mary Frances McMullin, Anna Armatys, Adrianna Spalek, Joanna Waclaw, Mihnea Tudor Zdrenghea, Laurence Legros, Francois Girodon, Krzysztof Lewandowski, Anna Angona Figueras, Jan Samuelsson, Aitor Abuin Blanco, Pascale Cony-Makhoul, Angela Collins, Chloe James, Rajko Kusec, Marie Lauermannova, Maria Soledad Noya, Malgorzata Skowronek, Lukasz Szukalski, Anna Szmigielska-Kaplon, Marielle Wondergem, Iryna Dudchenko, Joanna Gora-Tybor, Kamel Laribi, Anna Kulikowska De Nalecz, Jean-Loup Demory, Katell Le Du, Sonja Zweegman, Carlos Besses Raebel, Radek C. Skoda, Stephane Giraudier, Martin Griesshammer, Jean-Jacques Kiladjian, Claire N Harrison

Blood (2023) 142 (Supplement 1): 748.

https://doi.org/10.1182/blood-2023-185108

Published: 2023

Journal Articles

CD16, CD57 and DNAM-1 Positive NK Cells Predict MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Bortezomib, Thalidomide and Dexamethasone

Charlotte L.B.M. Korst, Carolien Duetz, Wassilis S.C Bruins, A. Vera de Jonge, Kaz Groen, Christie P.M. Verkleij, Kristine A. Frerichs, Meliha Cosovic, Inoka Twickler, Rosa Rentenaar, Merve Eken, Paola Homan-Weert, Philippe Moreau, Pieter Sonneveld, Sonja Zweegman, Tuna Mutis, Niels W.C.J. Van De Donk

Blood (2023) 142 (Supplement 1): 3314.

https://doi.org/10.1182/blood-2023-177560

Published: 2023

Journal Articles

Baseline CD57 + and CD16 + NK-Cells Predict Treatment Outcome in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Ixazomib-Dexamethasone

Wassilis S.C Bruins, Carolien Duetz, Kaz Groen, Charlotte L.B.M. Korst, A.Vera de Jonge, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Paola Homan-Weert, Christie P.M. Verkleij, Kristine A. Frerichs, Niels WCJ van de Donk, Sonja Zweegman, Tuna Mutis

Blood (2023) 142 (Supplement 1): 1940.

https://doi.org/10.1182/blood-2023-189527

Published: 2023

Journal Articles

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Blood (2023) 142 (Supplement 1): 342.

https://doi.org/10.1182/blood-2023-180006

Published: 2023

Journal Articles

Dual Split-Signaling TIM3+CLEC12a Targeting CAR T-Cells with Optimized Signaling As a Safe Potential Therapy for Acute Myeloid Leukemia

Jort J Van Der Schans, Paresh Vishwasrao, Noortje Van Gils, Mashhour Hosny, Ziyu Wang, Jennemiek Van Arkel, Sonja Zweegman, Maria Themeli, Gert Ossenkoppele, Niels W.C.J. van de Donk, Arjan A. Van de Loosdrecht, Linda Smit, Tuna Mutis

Blood (2023) 142 (Supplement 1): 883.

https://doi.org/10.1182/blood-2023-180799

Published: 2023

Journal Articles

Risk of Severe Sars-Cov-2 Infections in COVID-19 Vaccinated Individuals with Hematologic Malignancies (SAVE HEM): A Nationwide Cohort Study in the Netherlands

Quincy Hofsink, Sabine Haggenburg, Birgit I. Lissenberg-Witte, Abraham Goorhuis, Mette D. Hazenberg, Caroline E. Rutten, Sonja Zweegman, Jeanet Kemmeren, Nicolette F. de Keizer, Peter C. Huijgens, Avinash G. Dinmohamed, Susan van den Hof, Brechje de Gier, Mirjam Knol, Susan Hahné, Jarom Heijmans, Inger S. Nijhof

Blood (2023) 142 (Supplement 1): 546.

https://doi.org/10.1182/blood-2023-188561

Published: 2023

Journal Articles

Equality: trial and error?

David G. J. Cucchi, Sonja Zweegman

Blood (2023) 142 (3): 212–214.

https://doi.org/10.1182/blood.2023020327

Published: 2023

Journal Articles

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Blood (2023) 141 (6): 579–591.

https://doi.org/10.1182/blood.2022016782

Published: 2023

Includes: Supplemental data

Journal Articles

Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study

Man Wai Tang, Deborah van der Tuin, Mesire Aydin, Jarom Heijmans, Arjan A. van de Loosdrecht, Ellen Meijer, Caroline E. Rutten, Marielle Wondergem, Jeroen J.W.M. Janssen, Marjolein Donker, Mette D. Hazenberg, Sonja Zweegman, Bart J. Biemond, David C. de Leeuw, Erfan Nur

Blood (2022) 140 (Supplement 1): 3287–3289.

https://doi.org/10.1182/blood-2022-163042

Published: 2022

Journal Articles

High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children's Oncology Group Trial AALL1231

Margot S.F. Roeten, Johan van Meerloo, Zinia Kwidama, Gaye Jenkins, Suzanne N. van Dijk, David T. Teachey, Meenakshi Devidas, Mignon L. Loh, Gertjan J.L. Kaspers, Sonja Zweegman, Gerrit Jansen, Jacqueline Cloos, Terzah M. Horton

Blood (2022) 140 (Supplement 1): 9183–9184.

https://doi.org/10.1182/blood-2022-162412

Published: 2022

Journal Articles

Preclinical Activity of Allogeneic CS1-Specific CAR T-Cells (UCARTCS1) in Multiple Myeloma

Charlotte L.B.M. Korst, Wassilis S.C. Bruins, Meliha Cosovic, Christie P.M. Verkleij, Inoka Twickler, Diane Le Clerre, Isabelle Chion-Sotinel, Sonja Zweegman, Roman Galetto, Tuna Mutis, Niels WCJ Van De Donk

Blood (2022) 140 (Supplement 1): 4215–4216.

https://doi.org/10.1182/blood-2022-157950

Published: 2022

Journal Articles

Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Blood (2022) 140 (Supplement 1): 8347–8349.

https://doi.org/10.1182/blood-2022-168991

Published: 2022

Journal Articles

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

Blood (2022) 140 (Supplement 1): 1566–1567.

https://doi.org/10.1182/blood-2022-170249

Published: 2022

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Blood (2022) 140 (Supplement 1): 4420–4422.

https://doi.org/10.1182/blood-2022-165942

Published: 2022

Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Blood (2022) 140 (Supplement 1): 7536–7537.

https://doi.org/10.1182/blood-2022-159169

Published: 2022

Journal Articles

Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy

Sabrin Tahri, Madelon M.E. de Jong, Cathelijne Fokkema, Natalie Papazian, Zoltan Kellermayer, Michael Vermeulen, Mark van Duin, Pieter van de Woestijne, Kazem Nasserinejad, Elona Saraci, Mattia D'Agostino, Francesca Gay, Vincent H.J. van der Velden, Niels WCJ Van De Donk, Annemiek Broijl, Pieter Sonneveld, Sonja Zweegman, Tom Cupedo

Blood (2022) 140 (Supplement 1): 9982–9984.

https://doi.org/10.1182/blood-2022-164812

Published: 2022

Journal Articles

Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Blood (2022) 140 (Supplement 1): 1957–1959.

https://doi.org/10.1182/blood-2022-169164

Published: 2022

NARROW

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Maintain maintenance in multiple myeloma?

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

CD16, CD57 and DNAM-1 Positive NK Cells Predict MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Bortezomib, Thalidomide and Dexamethasone

Baseline CD57 + and CD16 + NK-Cells Predict Treatment Outcome in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Ixazomib-Dexamethasone

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Dual Split-Signaling TIM3+CLEC12a Targeting CAR T-Cells with Optimized Signaling As a Safe Potential Therapy for Acute Myeloid Leukemia

Risk of Severe Sars-Cov-2 Infections in COVID-19 Vaccinated Individuals with Hematologic Malignancies (SAVE HEM): A Nationwide Cohort Study in the Netherlands

Equality: trial and error?

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study

High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children's Oncology Group Trial AALL1231

Preclinical Activity of Allogeneic CS1-Specific CAR T-Cells (UCARTCS1) in Multiple Myeloma

Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy

Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only